2262-2263 / 2437
Costa
et al 2015, J Clin Oncol; 33 (17): 1881-1888
ALK+ advanced NSCLC
& brain metastases
Brain metastases in patients with ALK-positive NSCLC
275 patients
613 patients
PROFILE trials 1005 & 1007
brain mets
previously untreated
no brain mets
no. pts
166
613
PFS median
5.9m
(4.2-6.9)
8.8m
(7.9-9.9)
6 m OS
77%
(67-85)
85%
(81-87)